We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Sareum Holdings Plc | LSE:SAR | London | Ordinary Share | GB00BMC3RJ87 | ORD GBP 0.0125 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.00 | 3.92% | 26.50 | 26.00 | 27.00 | 26.50 | 25.50 | 25.50 | 233,295 | 11:00:46 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -3.19M | -0.0296 | -8.95 | 27.53M |
Date | Subject | Author | Discuss |
---|---|---|---|
23/4/2024 07:41 | Critical, your posts are so difficult to understand.'Mr Steel, James and individuals via TELEGRAM'. What does it all mean? Can you bullet point your comments into readable sentences so I can understand your points. | peaceandlove | |
23/4/2024 07:31 | Really good post Iamhappy. I've always suspected the MHRA may have felt that Sareum's novel formulation was not a sufficient innovation to expose fit and healthy volunteer-patients to the risks of the clinical trial in the UK hence their decision to move to Australia. I have also said many times we as potential investors don't know if 1801 works let alone Sareum. The Clinical Trial is a phase 1. This assesses only the basic safety of the new molecule and has nothing to do with whether it will work or not. The happy clappers are certain 1801 is going to license for several £billion. I just can't see it myself. Let's get the Phase 1 data first. If successful and they eventually start to show that their prototype drug is safe enough to administer to sick patients in the future (Phase 2a and then Phase 2b) maybe I'll have a punt, but until then it's a wait and see. A long way to go yet. And more money will be needed. At present there is no proven products and no revenue. Sareum's business model was always to license pre clinical or early clinical - I just can't see that happening in the short term. In the meantime, we have the gruesome twosome on here being vile and disgusting. Also, the happy clappers ramping the cr*p out of Sareum without a shed of evidence to back up their claims. | peaceandlove | |
22/4/2024 21:51 | Come on critical... Explain foi to me... Tell us all whens the takeover... What does emma walmsley think... Remind us of a time you spoke to thoth... | wolfofwallstreets | |
22/4/2024 21:26 | Get a life...if ever there was words that apply to you. You're just a mad ramper... You didn't understand FOI rules... When's the takeover happening.. | wolfofwallstreets | |
22/4/2024 20:47 | Critical.. You don't even know how FOI works.. You aren't taken seriously here... Did emma walmsley tell you when the takeover is happening | wolfofwallstreets | |
22/4/2024 20:26 | Exactly iamhappy1 but so few wish to discuss the progress from the rather groundbreaking research which has progressed. I suspect your boiler room mates will accept at some point that the continued buying from genuine investors will outweigh your playing the share given the information you have attained from Mr Steel and his cohorts. I truly hope that dome on lse see through the game some ay on lse. But you are probably involved. Be a SAD day if this share was manipulated by James and the wealth of info that might construct individuals via TELEGRAM. | criticalthinker1 | |
22/4/2024 20:19 | The principal financial risks are the ability to raise sufficient funds to support the Company through to profitability and failure to secure licensing agreements There Always Remains The Possibility That A Similar Drug Is Being Developed By A Competitor That Demonstrates Greater Efficacy Or A Better Safety Profile. Alternatively, A Similar Drug In Development May Conclude A Licensing Deal Or Reach A Later Stage Of Development Before We Are Able To, Thus Reducing The Likelihood Of Sareum Securing A Licensing Agreement | iamhappy1 | |
22/4/2024 20:02 | And if you want the conclusive point its just below from the link I posted In conclusion, the current large-scale, cross-sectional study revealed that compared to other treatment methods, IL-23 inhibitor treatment decreased the risk of COVID-19 and long COVID. These findings support the suggestion to avoid preventive cessation of IL-23 inhibitor treatment. In fact, in cases of moderate-to-severe plaque psoriasis that require systemic treatment, IL-23 inhibitor treatment should be positively considered. However, further studies with longer follow-up are warranted to provide broader insight into the influence of this class of drugs on COVID-19 risk. So I appreciate the end part of my post which is a paste ...but read it! Further studies... Today is Monday. Tomorrow is Tuesday. I'm one further day towards my end. But I will not allow obfuscation and posters who can't respond to genuine aware investments to be shorted and denounced given the 'potential'. I love hearing about real posters doing real things such as flying, being supportive of their offspring being our future. I get that!! I'm up for a discussion point. Let's request an EGM and no time limit. Let's get a discussion going with the board snd PH and our IR department. Especially given my find that I already knew about from previous findx I have licked away ready for release when appropriate. | criticalthinker1 | |
22/4/2024 19:49 | Critical pay attention to words like "may" & "might" similar to your previous post from 2014! the science has moved on in the last decade | iamhappy1 | |
22/4/2024 19:07 | The link does work if you press on read thread and then you can open it. Not sure why but my view of my post dosnt show the link but does if you do the above. All best Steadydanny 👌 | criticalthinker1 | |
22/4/2024 18:57 | This is from sciencedirect.com 30 January 2024 re covid and psoriasis I hope the link works. You will note where the research is being done and 'possibly' entertain the recent Patents Sareum have had approved. As I purported before and I'm not going to rise to posters who are purely dismissive...but I asked the other day to discuss interleukins...silen Anyway if the link dosnt work it's quiteceasy to find it re above information. All best Steadydanny I'm hopeful that genuine individuals are aware of the noteable excess deaths albeit they should be lower given the '28 days' scenario that drove numerous countries into noteable ongoing debt. When you see it you can't unsee it. Even the halfwits who post on here negativity might realise they are just useful idiots. | criticalthinker1 | |
22/4/2024 18:36 | The rampers are out in force on LSE. It's so entertaining. They never learn 🤣 | peaceandlove | |
22/4/2024 15:39 | He needs a new share to ramp... | wolfofwallstreets | |
22/4/2024 15:29 | Horrid, you need help 😆🤣 | peaceandlove | |
22/4/2024 13:26 | I'm seeing a share price that's back to normal... All for you thoth!! ❤️ | wolfofwallstreets | |
22/4/2024 10:38 | L2 Pete/Wolf/Peace ? | horridhenry | |
22/4/2024 10:32 | come on everyone join in with us and buy at 20p, if it gets there | horridhenry | |
22/4/2024 10:24 | our cleaner is getting some, and telling her friends as well. Are you our cleaner Pete? | horridhenry | |
22/4/2024 07:56 | Sadoldgit doesn't know F all about the share price rising. Why would it go up in a straight line? The only reason it's recovered from 10p is because the market likes the fact the board can call on the happy clappers at anytime for a cash injection. What else is there apart from Phase 1 safety data in the horizon. I like to keep it real and not make assumptions. I challenge anyone to tell me different. | peaceandlove |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions